Clinical trial
Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast…
NCT00128856 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00128856 |
|---|---|
| Title | Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients |
| Official title | Phase II Pharmacogenomic and Clinical Trial for the Administration of Gemcitabine-doxorubicin-paclitaxel (GAT) as Neoadjuvant Treatment of Patients With Stage III Breast Cancer |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Eli Lilly and Company Industry Bristol-Myers Squibb |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Adriamycine, Paclitaxel |
| Enrollment | 46 |
| Start date | Mar 1, 2003 |
| Primary completion | Jan 1, 2015 |
| Completion | Jan 1, 2015 |
| First posted | Aug 10, 2005 |
| Last update posted | Mar 6, 2023 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: